French cosmetics behemoth L’Oréal is set to acquire Medik8, a British skincare brand renowned for its vitamin A-based anti-aging products.
The deal, announced Monday by Medik8’s current owner, UK-based private equity firm Inflexion, marks another strategic move by L’Oréal to deepen its presence in the rapidly expanding and highly lucrative dermatological skincare market.
While the financial terms of the acquisition were not disclosed, the addition of Medik8 is poised to enhance L’Oréal’s already formidable dermatological beauty division.
This unit, which boasts powerhouse brands such as CeraVe, La Roche-Posay, and SkinCeuticals, has been L’Oréal’s fastest-growing segment in recent years.
It achieved impressive revenues of 7 billion euros ($7.99 billion) last year, following nearly 10% growth from the year prior.
This division is also notable for having the highest profit margin among L’Oréal’s four main business units.
The surge in consumer interest for science-backed skincare products has been a primary driver of this division’s success.
However, growth in this popular category has recently shown signs of moderation due to intensifying competition from both established players and emerging niche brands.
Strategic acquisition drive: reviving growth and expanding reach
L’Oréal executives have openly stated this year that the company is actively pursuing acquisitions as a strategy to revive flagging growth in certain areas and to further expand its global footprint.
The Medik8 purchase aligns perfectly with this objective.
This latest acquisition follows L’Oréal’s move in December to buy Korean skincare brand Dr.G and its acquisition of a minority stake in Oman-based luxury perfume house Amouage last year, signaling a consistent appetite for strategic additions to its portfolio.
Inflexion, the private equity firm selling Medik8, will retain a minority shareholding in the brand as part of the transaction.
According to a statement from Inflexion, “The partnership with L’Oreal will allow Medik8 to deepen its presence in existing markets and expand globally.”
This suggests a collaborative approach to nurturing Medik8’s future growth under L’Oréal’s ownership, leveraging the French giant’s extensive global distribution network and marketing prowess.
The post L’Oréal buys Medik8, expanding its portfolio in anti-aging skincare market appeared first on Invezz